D. Price

发表

AC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson's disease rat model.

K. Mcfarland, D. Bonhaus, Jian-Nong Ma, 2013, ACS chemical neuroscience.

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies

E. Masliah, E. Rockenstein, B. Spencer, 2016, Scientific Reports.

Validation of retinal imaging for characterizing alpha-synuclein-eGFP deposition in a transgenic mouse model of Parkinson ’ s Disease / Dementia with Lewy Bodies

E. Masliah, E. Rockenstein, D. Bonhaus, 2014 .

NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

Agata Habas, D. Bonhaus, D. Price, 2022, International journal of inflammation.

Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity

Mark H. Ellisman, Brian Spencer, Diana L. Price, 2010, PloS one.

Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease

K. Mcfarland, D. Bonhaus, D. Price, 2012, Behavioural pharmacology.

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies

E. Masliah, E. Rockenstein, B. Spencer, 2014, Molecular Neurodegeneration.

Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury

Milos Pekny, Eric A Bushong, Mark H Ellisman, 2006, Proceedings of the National Academy of Sciences.

Distribution of rSlo Ca2+-activated K+ channels in rat astrocyte perivascular endfeet

Mark Ellisman, T. Schwarz, D. Price, 2002, Brain Research.

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

M. Chesselet, E. Masliah, I. Tsigelny, 2016, Brain : a journal of neurology.

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease

E. Masliah, E. Rockenstein, W. Wrasidlo, 2018, Scientific Reports.

Neuroprotective effects of the anti‐cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders

Igor F Tsigelny, Diana Price, Valentina L Kouznetsova, 2014, British journal of pharmacology.

High-resolution large-scale mosaic imaging using multiphoton microscopy to characterize transgenic mouse models of human neurological disorders

Mark H. Ellisman, Maryann E. Martone, Steven Peltier, 2007, Neuroinformatics.

Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists.

R. Abagyan, A. Orry, W. Wrasidlo, 2021, Bioorganic & medicinal chemistry letters.

Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats

M. Geyer, D. Price, A. Halberstadt, 2012, Pharmacology Biochemistry and Behavior.

The cell-centered database

Simone Santini, Amarnath Gupta, Mark H. Ellisman, 2007, Neuroinformatics.

NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease.

E. Masliah, W. Wrasidlo, D. Bonhaus, 2021, Brain : a journal of neurology.

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease

K. Mcfarland, D. Bonhaus, D. Price, 2011, Behavioural pharmacology.

Multiscale imaging characterization of dopamine transporter knockout mice reveals regional alterations in spine density of medium spiny neurons

Mark Ellisman, M. Martone, M. Caron, 2011, Brain Research.